Drugs / IMG-004
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT05349097 | Aug 2022 → May 2024 | — | Inmagene LLC | Completed | No outcome recorded |
Press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2022-08-09 | Hutchison Medipharma Limited | Inmagene and HUTCHMED Announce First Participant in Global Phase I Trial of IMG-004 hutch-med.com ↗ |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | IMG-004 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05349097 ↗ |
| Route | Oral | “single oral dose of 30mg IMG-004” NCT05349097 ↗ |